Amalgent Therapeutics
Pharmaceutical Companies
Why pick this one
Amalgent Therapeutics develops AMGT-0220, a fixed-dose opioid/pramipexole combination supported by a 2024 pilot study and three issued U.S. patents.
Best for
- Opioid pain-management development focused on reducing opioid exposure
- Research involving dopamine-modulated opioid combinations
- Pharmaceutical licensing or partnership discussions around AMGT-0220
- Severe-pain therapeutic development
Look elsewhere if
- Immediate patient prescriptions or retail medication dispensing
- Routine pharmacy services
- Emergency pain treatment
- Businesses seeking an already marketed opioid product
Specialties
- Fixed-dose opioid and dopamine-modulating adjuvant combinations
- AMGT-0220 development for severe pain
- Opioid dose-reduction strategies
- Opioid reward and tolerance mitigation
What makes them different
- $2.8 million in NIH/NIDA non-dilutive funding
- Three issued U.S. patents covering opioid combination therapies, dose reduction, tolerance, dependence, and withdrawal
- Exclusive worldwide license from East Carolina University
- Seven peer-reviewed publications supporting the technology
- Published 2024 randomized, double-blind pilot study of an opioid/pramipexole combination for acute renal colic
Distilled from this business's own website.
Contact & Location
- Address
- 300 E 1st St, Greenville, NC 27858-1201
- Website
- https://www.amalgent.com
Services
- Pharmaceutical research and development
- Preclinical and clinical drug development
- Opioid pain-management platform commercialization
- Therapeutic licensing and business development